BRAINSTORM CELL THERAPEUTICS (BCLI) Fundamental Analysis & Valuation

NASDAQ:BCLI • US10501E3009

1.17 USD
-0.03 (-2.5%)
At close: Jul 17, 2025
0.67 USD
-0.5 (-42.74%)
After Hours: 7/17/2025, 8:04:41 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BCLI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

Taking everything into account, BCLI scores 1 out of 10 in our fundamental rating. BCLI was compared to 520 industry peers in the Biotechnology industry. BCLI may be in some trouble as it scores bad on both profitability and health. BCLI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. BCLI Profitability Analysis

1.1 Basic Checks

  • In the past year BCLI has reported negative net income.
  • In the past year BCLI has reported a negative cash flow from operations.
  • BCLI had negative earnings in each of the past 5 years.
  • In the past 5 years BCLI always reported negative operating cash flow.
BCLI Yearly Net Income VS EBIT VS OCF VS FCFBCLI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -310.45%, BCLI is doing worse than 92.99% of the companies in the same industry.
Industry RankSector Rank
ROA -310.45%
ROE N/A
ROIC N/A
ROA(3y)-443.44%
ROA(5y)-295.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCLI Yearly ROA, ROE, ROICBCLI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K 4K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BCLI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCLI Yearly Profit, Operating, Gross MarginsBCLI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. BCLI Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for BCLI has been increased compared to 1 year ago.
  • The number of shares outstanding for BCLI has been reduced compared to 5 years ago.
  • BCLI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BCLI Yearly Shares OutstandingBCLI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
BCLI Yearly Total Debt VS Total AssetsBCLI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • BCLI has an Altman-Z score of -103.72. This is a bad value and indicates that BCLI is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -103.72, BCLI is doing worse than 96.04% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -103.72
ROIC/WACCN/A
WACCN/A
BCLI Yearly LT Debt VS Equity VS FCFBCLI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

  • BCLI has a Current Ratio of 0.21. This is a bad value and indicates that BCLI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of BCLI (0.21) is worse than 94.96% of its industry peers.
  • A Quick Ratio of 0.21 indicates that BCLI may have some problems paying its short term obligations.
  • The Quick ratio of BCLI (0.21) is worse than 94.78% of its industry peers.
Industry RankSector Rank
Current Ratio 0.21
Quick Ratio 0.21
BCLI Yearly Current Assets VS Current LiabilitesBCLI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. BCLI Growth Analysis

3.1 Past

  • BCLI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.54%, which is quite impressive.
EPS 1Y (TTM)21.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 22.11% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y33.08%
EPS Next 2Y25.71%
EPS Next 3Y18.1%
EPS Next 5Y22.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCLI Yearly Revenue VS EstimatesBCLI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2028 2029 2030 2031 2032 100M 200M 300M
BCLI Yearly EPS VS EstimatesBCLI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

0

4. BCLI Valuation Analysis

4.1 Price/Earnings Ratio

  • BCLI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BCLI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCLI Price Earnings VS Forward Price EarningsBCLI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCLI Per share dataBCLI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5 -2

4.3 Compensation for Growth

  • BCLI's earnings are expected to grow with 18.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.71%
EPS Next 3Y18.1%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BCLI Dividend Analysis

5.1 Amount

  • No dividends for BCLI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

BCLI Fundamentals: All Metrics, Ratios and Statistics

BRAINSTORM CELL THERAPEUTICS

NASDAQ:BCLI (7/17/2025, 8:04:41 PM)

After market: 0.67 -0.5 (-42.74%)

1.17

-0.03 (-2.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15
Earnings (Next)08-12
Inst Owners12.89%
Inst Owner Change0%
Ins Owners12.88%
Ins Owner Change0%
Market Cap9.29M
Revenue(TTM)N/A
Net Income(TTM)-11.09M
Analysts82.86
Price Target15.47 (1222.22%)
Short Float %4.01%
Short Ratio0.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.47%
Min EPS beat(2)-31.58%
Max EPS beat(2)54.52%
EPS beat(4)2
Avg EPS beat(4)5.98%
Min EPS beat(4)-31.58%
Max EPS beat(4)54.52%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)21.33%
PT rev (3m)21.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0.32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.07
EYN/A
EPS(NY)-0.99
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.96
OCFYN/A
SpS0
BVpS-0.94
TBVpS-0.94
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -310.45%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-443.44%
ROA(5y)-295.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.21
Quick Ratio 0.21
Altman-Z -103.72
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
EPS Next Y33.08%
EPS Next 2Y25.71%
EPS Next 3Y18.1%
EPS Next 5Y22.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.53%
EBIT Next 3Y-9.08%
EBIT Next 5Y74.22%
FCF growth 1Y60.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.95%
OCF growth 3YN/A
OCF growth 5YN/A

BRAINSTORM CELL THERAPEUTICS / BCLI FAQ

What is the ChartMill fundamental rating of BRAINSTORM CELL THERAPEUTICS (BCLI) stock?

ChartMill assigns a fundamental rating of 1 / 10 to BCLI.


Can you provide the valuation status for BRAINSTORM CELL THERAPEUTICS?

ChartMill assigns a valuation rating of 0 / 10 to BRAINSTORM CELL THERAPEUTICS (BCLI). This can be considered as Overvalued.


What is the profitability of BCLI stock?

BRAINSTORM CELL THERAPEUTICS (BCLI) has a profitability rating of 0 / 10.


Can you provide the financial health for BCLI stock?

The financial health rating of BRAINSTORM CELL THERAPEUTICS (BCLI) is 1 / 10.


What is the expected EPS growth for BRAINSTORM CELL THERAPEUTICS (BCLI) stock?

The Earnings per Share (EPS) of BRAINSTORM CELL THERAPEUTICS (BCLI) is expected to grow by 33.08% in the next year.